Land Mark National Clinical Trial

Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be improving clinical symptoms in Chinese COVID-19 patients and similar effects have been demonstrated in French patients. We shall evaluate the effectiveness of :

  • Azithromycin alone
  • Hydroxychloroquine alone
  • Oseltamivir alone
  • Combinations of hydroxychloroquine with Oseltamivir
  • Hydroxychloroquine with azithromycin
  • Oseltamivir with azithromycin
  • combination of all three drugs

on respiratory viral loads within a comprehensive cohort study, a multicenter, mulitarm-multistage, adaptive, randomized controlled trial and will evaluate these treatment modalities, among eligible COVID-19 infected patients receiving standard supportive care who consent to randomization following a new diagnosis in Pakistan. Those not consenting to randomization will be followed up for outcomes of COVID-19 infection with supportive care only. The primary outcome shall be clearing of coronavirus nucleic acid (covid19) from throat and nasal swabs. The Viral loads shall be checked by Reverse Transcription-Quantitative Polymerase Chain Reaction (RT-qPCR).